Effect of ultrasound on human umbilical cord peri-vascular cells

Taghreed A. Aldosary, Hasan Uludag, Michael R. Doschak, Tarek El-Bialy

1. National Guard Health Affairs, Community and Preventive Medicine, Jeddah, Saudi Arabia. 2. University of Alberta, Department of Chemical and Material Engineering, Edmonton, Canada. 3. University of Alberta, Faculty of Pharmacy & Pharmaceutical Sciences, Edmonton, Canada. 4. University of Alberta, School of Dentistry, Faculty of Medicine & Dentistry, Edmonton, Canada.

Correspondence: Tarek El-Bialy, Associate Professor. Address: Orthodontics and Biomedical Engineering, 7-020D Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton T6G 2E1, Canada. Email: telbialy@ualberta.ca

Received: June 16, 2015  Accepted: August 6, 2015  Online Published: August 14, 2015

DOI: 10.5430/jbei.v1n1p70  URL: http://dx.doi.org/10.5430/jbei.v1n1p70

Abstract

Background: Tissue engineering involves using different types of stem cells. One of the roadblocks in tissue engineering is the scant supply of stem cells. The potential use of human umbilical cord peri-vascular Cells (HUCPVCs) has recently been considered as an important cell source for tissue engineering applications. The objective of this study was to explore the effect of low intensity pulsed ultrasound (LIPUS) on HUCPVCs.

Materials and methods: HUCPVCs were divided into two groups: treatment group which received 30 mW/cm² LIPUS for 10 minutes (1, 7, and 14 days) and control group which received sham treatment. The study groups were evaluated for cell count, alkaline phosphatase (ALP) activity, DNA-content, gene expression, and immunophenotype.

Results: There was no significant differences in cell count, ALP, DNA-content, and CD-90 between LIPUS and control groups. A significantly higher expression of OSP and PCNA was observed on day 14 in LIPUS treatment group.

Conclusion: LIPUS application for 10 minutes per day for 14 days enhanced OSP and PCNA expression without significant increase in cell count of HUCPVCs. Future research may aim at exploring different LIPUS applications (different time and frequency) to optimize HUCPVCs proliferation.

Key words
Low intensity pulsed ultrasound, Stem cells, Human umbilical cord peri-vascular cells

1 Introduction

An adequate source of mesenchymal progenitor cells (MPCs) is increasingly needed for cell therapy and tissue engineering. The interest in MPCs has recently increased as a tool for therapeutic applications because of their unique characteristics, including the relative ease of culture and the high potential for their expansion in vitro. Bone marrow has been historically the primary source of MPCs. However, the harvest of cells from bone marrow involves an invasive procedure that may predispose the donor site to risk of infection and morbidity. Another shortcoming is that the proliferation and differentiation capacity of bone marrow MPCs decreases with age.
Umbilical cord (UC) cells have been investigated and it has been shown that cells from perivascular (PV), Wharton's jelly (WJ) contain significantly lesser CD40+ non-stem cell contaminants (26%-27%) compared to cells from other UC compartments [6]. The same authors showed that cells isolated from (WJ) can offer the best clinical utility [6]. One potential solution to this problem is the possible utilization of human umbilical cord peri-vascular cells (HUCPVCs), which comprise a cell population capable of exhibiting a functional mesenchymal phenotype [2-5]. Undifferentiated stromal mesenchymal cells from umbilical cord are immunologically suppressed and therefore may be considered for cell transplantation [6-9]. Multiple studies have shown that HUCPVCs are negative for the endothelial/hematopoietic cell markers CD34, CD45, and MHCII, but stained positively for MSC markers, namely CD90 and MHC1 [3, 5, 10-12]. These cells demonstrated the possibility to differentiate into osteogenic cells after 3 weeks, as well as into multiple mesenchymal lineages [3, 11-13]. It has been reported that HUCPVCs can be differentiated into osteocytes after 2 weeks [12]. The HUCPVCs continued to test negative for MHCII and CD31, but positive for MHC1, similar to bone marrow MSCs [13]. Furthermore, several in vitro studies revealed that HUCPVCs were negative to CD34, CD45, CD31, and MHCII, but persistently stained positive for CD90 [14-18]. These findings eliminated the possibility of endothelial or hematopoietic contamination in this cell population and have provided a pure MSC progenitor precursor for therapeutic purposes.

Therapeutic application of ultrasound has proven to facilitate healing of bone fractures with special significance of the low-intensity pulsed ultrasound (LIPUS) [19]. The stimulatory effect of LIPUS application was related to an increase in the integration of calcium ions into osseous and soft tissues [20]. LIPUS also appeared to stimulate the expression of genes that mediate the healing process, including the proteoglycan aggrecan and IGF (Insulin-like Growth Factor) expression [20]. A previous study has shown that a single 50-second LIPUS application to human umbilical cord-derived cells increased cell proliferation especially in the first few days (3-5 days) [21]. However, the applied LIPUS pulse repetition frequency (40 KHz) was too high compared to the clinically used LIPUS pulse repetition frequency (1 KHz). Recently, it has been shown that LIPUS enhances bone marrow and adipose stem cell osteogenic differentiation, however the technique is still yet to be optimized [12]. The aim of this study was to explore whether the LIPUS has a stimulatory effect on HUCPVCs proliferation while maintaining their phenotypic characteristics. Other types of ultrasound (ultrasound-targeted microbubble destruction (UTMD) has been used recently to mobilize bone marrow stem cells for tissue repair [23]. The ultrasound parameters used in their study (US frequency = 1 MHz; duty cycle = 10%; peak negative pressure = 0.6 W/cm² (0.35 MPa); total irradiation time = 30 s; dosage of MBs = 10⁶/mL) however were different from those that have been used for therapeutic application.

## 2 Material and methods

### 2.1 Cell culture

Approval was obtained from Health Research Ethics Board, University of Alberta, Edmonton, Canada (approval number 6431). Umbilical cords were obtained, following informed written consent, from patients undergoing full-term caesarean sections. HUCPVCs were isolated according to methods described before [5]. Cells at passage 1 were thawed and were seeded into three T-75 cm² tissue culture flasks (Sigma Aldrich, Oakville, ON, Canada) containing Dulbecco’s modified Eagle’s medium with low glucose (DMEM-LG) (GIBCO, Invitrogen, Burlington, ON, Canada) supplemented with 15% Fetal Bovine Serum (FBS) (GIBCO, Invitrogen, Burlington, ON, Canada), and 1% Antibiotic-Antimycotic (Sigma Aldrich, Oakville, ON, Canada) at initial cell density of 3.6 ×10⁶ /ml. Cells were incubated at 37°C and 5% CO₂ then expanded for 10 days till P4 and media was changed every 2-3 days. When the cell confluence reached 80% (4.2 ×10⁶ /ml), they were harvested and trypsinized using 0.25% Trypsin (GIBCO, Invitrogen), collected in 50 ml tubes, centrifuged, then seeded in nine 6 well plates (Sigma Aldrich, Oakville, ON, Canada) at (2 × 10⁴)/ ml [24, 25]. 27 wells per group were treated for 10 min/day by 4 ultrasound devices “Exogen LIPUS transducers, Smith and Nephew, Mississauga, ON, Canada” with 4 transducers placed immediately below the wells and coupled to the well bases with standard ultrasound coupling gel [24]. The ultrasound transducers produce 1.5 MHz ultrasound waves comprising 200 µs bursts at a pulse repetition frequency of 1 KHz and output intensity of 30 mW/cm². Transducers were calibrated before and after applications for consistency of
electrical waveforms (1 KHz modulation, 200 microseconds pulse duration, and 1.5 MHz pulse frequency) \[^{[22]}\] using TDS1012C-EDU digital oscilloscope (Tektronix, Canada), and calibrated for ultrasound intensity of 30 mW/cm\(^2\) using an ultrasound power-meter (model UPM-DT-1AV from Ohmic Instruments, Easton, MD, USA). The calibrations at the beginning and at the end of the experiments confirmed that the ultrasound devices provided stable ultrasound power output and maintained the desired parameters during the experiment. Temperature was maintained at 37°C within the incubator while LIPUS was applied. LIPUS was applied to cell culture plates (n=27) for 10 minutes per day for 1 day, 7 days and 14 days. The other control wells (n=27) were treated using the same transducers without turning the machines on (sham control). Each group was evaluated at each time point (1, 7 and 14 days).

2.2 Cell count

Cells were washed using PBS (GIBCO, Invitrogen, Burlington, ON, Canada) then trypsinized. Cells and medium were collected in 15 ml tubes for spinning (6 min/600rpm). The supernatant was vacuumed away. Cells were counted using Beckman Coulter Machine (Beckman coulter Canada Inc., Burlington, ON, Canada).

2.2.1 Alkaline phosphatase activity assay

HUCPVCs ALP activity was determined by the colorimetric assay at the indicated time points. ALP is a biochemical marker for cell differentiation of osteogenic lineage \[^{[21, 22, 24, 26, 27]}\]. Cells were washed with PBS and lysed with 2 mL of ALP buffer per well (0.5 M 2-amino-2-methyl-1-propanol and 0.1% Triton-X-100, pH 10.5). Two hours later, after lysis, 1 mL of lysed cells was used for DNA quantitation assay. Phosphatase substrate (p-nitrophenyl phosphate) (Sigma, Oakville, ON, Canada) was added to ALP buffer in 1 mg/ml (1:1) ratio. 100 µl of lysed cells and 100 µl of substrate mixture were loaded to each well into 96 well plate of a final concentration of 1 mg/mL. The changes in optical density (absorbance, 405 nm) were determined in a multiwell plate reader (ELX800 Universal Microplate Reader, Bio-Tek Instruments, Inc. in Winooski, Vermont, USA.) at periodic intervals 5, 10, 15, 30 minutes.

2.2.2 Cell proliferation & DNA quantification assay

Lysed cell solution(1 mL) was used to measure the amount of DNA with the CyQUANT Cell proliferation kit (Molecular Probe, Invitrogen, Burlington, ON, Canada). The CyQUANT cell proliferation kit assay relies on the measurement of DNA quantity through binding with fluorescent dye (Molecular Probe, Invitrogen, Burlington, ON, Canada). The extent of proliferation is determined by comparing cell’s DNA content for treated samples with untreated controls. The CyQUANT kit protocol requires cell binding with the dye solution, incubation for 30-60 minutes, and then measurement of fluorescence in a microplate reader (Fluoroskan Ascent, Thermo Labsystems, Finland). The assay is designed to produce a linear analytical response in a 96-well microplate (Molecular Probe, Invitrogen, Burlington, ON, Canada). DNA standard provided with the CyQUANT kit was utilized to determine the DNA concentrations in each group of cells. According to the manufacturer’s instructions, DNA was quantified using a fluorescence plate reader (excitation at 480 nm; emission at 527 nm).

2.2.3 Immunophenotyping using flow-cytometry analysis

Further characterization of expanded HUCPVCs at passage 4 using cell surface antigen phenotyping was performed on days 1, 7 and 14. The following cell-surface epitopes were labeled with anti-human antibodies: CD31(PECAM-1) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada), CD34-R-phycoerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), CD45-phycoerythrin (PE, BD Biosciences, Mississauga, ON, Canada), CD90 (Thy1) R-phycoerythrin (R-PE, BD Bioscience, Mississauga, ON, Canada), MHC I (HLA-A,B,C) R-phycoerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), and MHC II (HLA-DR) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada) (Becton Dickinson; Beckman Coulter, Mississauga, ON, Canada), FITC-conjugated sotype-mouse IgGa1 and PE-conjugated Isotype-mouse IgGk1 served as secondary antibodies (control antibodies). 10,000 labeled cells were acquired and analyzed using a FACScan flow cytometer running CellQuest software (Becton Dickinson, Mississauga, ON, Canada). Details about these markers are described in Table 1. HUCPVCs were suspended and prepared using standard direct staining protocols \[^{[28-30]}\].
### Table 1. Description of cell surface markers

<table>
<thead>
<tr>
<th>Markers</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD90</td>
<td>Mesenchymal stromal cell marker</td>
</tr>
<tr>
<td>CD31</td>
<td>Endothelial cell marker</td>
</tr>
<tr>
<td>CD34</td>
<td>Hematopoietic cells and vascular endothelium marker</td>
</tr>
<tr>
<td>CD45</td>
<td>Differentiated hematopoietic cell marker</td>
</tr>
<tr>
<td>MHC I</td>
<td>Recognized during graft rejection and found on all nucleated cells</td>
</tr>
<tr>
<td>MHCII</td>
<td>A marker for B-lymphocytes, macrophages and dendritic cells</td>
</tr>
</tbody>
</table>

### 2.2.4 Quantitative real-time-PCR analysis (Q-PCR)

RNA was isolated and cDNA was synthesized; total RNA was extracted from each triplicate group of both LIPUS treated and sham groups using the RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada). RNA samples were quantified fluorometrically at 260 nm using SYBRgreen (Molecular Probes, OR, USA), as recommended by the manufacturer. Single stranded DNA (cDNA) was synthesized from 1 µg of total RNA using the Omniscript Reverse Transcription kit (Qiagen, Mississauga, ON, Canada). Primers for real-time PCR were designed with Primer Express 2.0 software from Applied Biosystems (AB, Foster City, CA, USA). RT-PCR reactions were performed using TaqMan®Gene Expression Assays (Applied Biosystems AB, Foster City, CA, USA) and TaqMan®Gene Expression Assays protocol (Applied Biosystems AB, Foster City, CA, USA). The TaqMan®MGB probes and primers were premixed to a concentration of 18 µM for each primer and 5 µM for the probe. Amplifications were carried out in a final reaction volume of 10 µl. Gene’s assays ID and gene’s symbols were explained in Table 2; the reaction mixtures were aliquoted into 96-well ABI reaction plate. The plates was then placed in an ABI Prism 7500 fast system V 1.4.0 Applied Bio-system Q-PCR machine under the following conditions: stage 1 consisted of 95°C for 10 min; stage 2 consisted of 40 cycles of 95°C for 15 s, followed by 60°C for 1 min. The Q-PCR data were analyzed with SDS 7500 Fast system V.2.01 software (AB, Foster City, CA, USA).

### Table 2. Genes used for Q-PCR analysis

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Assay ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endogenous Control Human GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)</td>
<td>GAPDH</td>
<td>4333764F</td>
</tr>
<tr>
<td>Osteocalcin (OCN)</td>
<td>BGLAP</td>
<td>Hs00609452_g1</td>
</tr>
<tr>
<td>Osteopontin (OPN)</td>
<td>SPP1</td>
<td>Hs00959009_m1</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA)</td>
<td>PCNA</td>
<td>Hs99999177_g1</td>
</tr>
<tr>
<td>Nucleostemin (NST)</td>
<td>GNL3</td>
<td>Hs00205071_m1</td>
</tr>
</tbody>
</table>

### 2.3 Statistical analysis

Data are presented as mean ± standard deviation. MANOVA was used to compare the expansion capacities of treated (LIPUS) group and control (sham) group. A two-way ANOVA was used to analyze the flow-cytometry data and Q-PCR data. Differences were considered significant at \( P < .05 \). The SPSS software package (version 16.0; SPSS Inc., Chicago, IL, USA) was used for the statistical tests.

### 3 Results

The HUCPVCs were observed at day 1, 7 and 14 after the application of LIPUS. There was no significant difference in cell count (see Figure 1) or DNA content between the LIPUS-treated and control groups (see Figure 2). The ALP activity (normalized with DNA) was increased at day 1 in LIPUS-treated group but it was lower at day 7 as compared to
sham-treated group. ALP/DNA activity increased but not statistically significant at day 14 in LIPUS-treated group (see Figure 2).

**Figure 1.** Cellular morphology images of HUCPVCs. Control and treated with LIPUS 10 min/day on days 1 (A, B), 7 (C, D), and 14 (E, F) respectively in basic media.

**Figure 2.** HUCPV-normalization of ALP/DNA results after application of LIPUS 10 min/day (days 1, 7, and 14) in basic media, L = LIPUS, C = control, HUCPV = Human Umbilical cord Perivascular. Cells were at P4 (n=12), data represent quantification from 3 biological replicates, error has indicate standard deviation.

Immunophenotyping analysis was used to analyze cell surface markers on HUCPVCs at passage 4. HUCPVCs were negative for CD31 and MHCII. The HUCPVCs were also negative for CD34 and CD45. Conversely, they were strongly positive for CD90 and moderately positive for MHCII. LIPUS-treated HUCPVCs expressed a high level of CD90 at day 14 compared with Sham treated group (see Table 3, Figure 3). There was no statistically significant difference between LIPUS and control groups with regard to expression of any of the cell markers (see Table 3).

**Figure 3.** Flow-cytometry of HUCPV-C (isotype IgG, CD31, CD90, CD34, CD45, MHCII, and MHCII) treated with LIPUS 10 min/day on days 1, 7, and 14 in basic media; differences between LIPUS (L) and control (C). Cells were at P4 (n=27), data represent quantification from 3 biological replicates, error has indicate standard deviation.
Table 3. Comparison of cell surface markers expression of flow-cytometry results of HUCPV-SC (isotype IgG, CD31, CD90, CD34, CD45, MHC I, and MHC II) treated with LIPUS 10 min/day on days 1, 7, and 14: difference between LIPUS (L) and control (C) in basic media. The results expressed as Mean ± SD.

<table>
<thead>
<tr>
<th>Markers / BM</th>
<th>Day 1</th>
<th></th>
<th>Day 7</th>
<th></th>
<th>Day 14</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L</td>
<td>C</td>
<td>P-Value</td>
<td>L</td>
<td>C</td>
<td>P-Value</td>
</tr>
<tr>
<td>Isotype IgG</td>
<td>3 ± 0.9</td>
<td>8.3 ± 4</td>
<td>.2</td>
<td>27.3 ± 9.7</td>
<td>25.4 ± 8.1</td>
<td>.8</td>
</tr>
<tr>
<td>CD31</td>
<td>16.3 ± 8.8</td>
<td>19.8 ± 13.5</td>
<td>.8</td>
<td>41.6 ± 12.5</td>
<td>38.9 ± 10.9</td>
<td>.2</td>
</tr>
<tr>
<td>CD90</td>
<td>2211.9 ± 1644.4</td>
<td>3204 ± 689.6</td>
<td>.3</td>
<td>3896.9 ± 953.6</td>
<td>4394.2 ± 2033.9</td>
<td>.4</td>
</tr>
<tr>
<td>CD34</td>
<td>12.8 ± 5.7</td>
<td>22.5 ± 20.6</td>
<td>.5</td>
<td>45 ± 20.8</td>
<td>47.3 ± 30.2</td>
<td>.8</td>
</tr>
<tr>
<td>CD45</td>
<td>25.9 ± 27.9</td>
<td>14.5 ± 7</td>
<td>.8</td>
<td>67.6 ± 61.3</td>
<td>43.7 ± 24.7</td>
<td>.6</td>
</tr>
<tr>
<td>MHC I</td>
<td>346.2 ± 59.2</td>
<td>241.5 ± 38.9</td>
<td>.07</td>
<td>217.9 ± 69.1</td>
<td>219.9 ± 7.5</td>
<td>.8</td>
</tr>
<tr>
<td>MHC II</td>
<td>13.9 ± 4.6</td>
<td>22.8 ± 19.8</td>
<td>.4</td>
<td>41.1 ± 13.6</td>
<td>46 ± 27.5</td>
<td>.6</td>
</tr>
</tbody>
</table>

Figure 4. Q-PCR comparison of levels of nucleostemin, osteocalcin, osteopontin, and PCNA after their equalization to the endogenous control gene (GAPDH) between LIPUS (L) and control (C) on days 1, 7, and 14 in basic media. Cells were at P4 (n=27), data represent quantification from 3 biological replicates, error has indicate standard deviation.

The expressions of NST, PCNA, OCN and OPN were then investigated in LIPUS treated HUCPVCs (see Figure 4). The cells expressed a significantly higher level of OPN and PCNA in LIPUS-treated group (P<.01) at day 14 (see Figure 4, ...)
Table 4). However, no difference in NST expression was observed at day 1, 7 or 14. The level of OCN was almost 1.25 folds higher in the LIPUS treated group than the control at day 1 and 14, but was 1.25 folds less at day 7.

Table 4. Q-PCR compare Mean ± SD of Nucleostemin, Osteocalcin, Osteopontin and PCNA after their equalization to the endogenous control gene (GAPDH) between LIPUS (L) and control (C) at day 1, 7 and 14 in basic media

<table>
<thead>
<tr>
<th>Genes / BM</th>
<th>Day 1</th>
<th>Day 7</th>
<th>Day 14</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L</td>
<td>C</td>
<td>L</td>
</tr>
<tr>
<td>GAPDH</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>NST</td>
<td>1.58 ± 0.44</td>
<td>1.33 ± 0.32</td>
<td>0.79 ± 0.03</td>
</tr>
<tr>
<td>OCN</td>
<td>1.32 ± 0.27</td>
<td>0.82 ± 0.33</td>
<td>0.30 ± 0.04</td>
</tr>
<tr>
<td>OPN</td>
<td>1.18 ± 0.37</td>
<td>0.76 ± 0.21</td>
<td>1.06 ± 0.12</td>
</tr>
<tr>
<td>PCNA</td>
<td>1.38 ± 0.24</td>
<td>0.96 ± 0.28</td>
<td>0.33 ± 0.09</td>
</tr>
</tbody>
</table>

4 Discussion

In this study, we investigated the effect of LIPUS on the characteristics and proliferation capacity of HUCPVCs. The 10 minutes LIPUS application was chosen based on previous study by Zhou et al., 2004 [31] who reported that LIPUS showed its optimum stimulatory effect on skin fibroblasts when applied at 10 minutes per day for 7 days. Our results showed that LIPUS did not significantly increase HUCPVCs cell count after a 10 minute daily applications for days 1, 7, and 14. This is in disagreement with previous studies that showed that LIPUS has a stimulatory effect on a variety of cell lines, such as osteoblasts, chondrocytes, and marrow-derived stromal cells [32-35]. This could be due to the possibility that HUCPVCs react differently to LIPUS compared to other cells.

The precise cellular mechanisms that mediate the observed therapeutic action of LIPUS are still not fully understood [36-38]. Yoon et al. 2009 [21] proposed that LIPUS stimulation will increase the capacity of human umbilical cord mesenchymal stem cells to proliferate by releasing extracellular matrix from Wharton’s jelly and increasing the sensitivity of the cells to extracellular growth factors. However, it has been reported that cells from the Wharton’s jelly behave differently from HUCPVCs [6]. It has been shown that the ultrasound transmitted energy invoke a direct effect on cell membrane permeability and on the second messenger adenylate cyclase activity in periosteal cells [26]. Subsequent changes in ion channels or protein transport, as a result of altered second messenger pathway could modify the intracellular signals for gene expression [26, 27]. This may potentially be the same mechanisms that HUCPVCs respond to LIPUS as in our study, however that observation needs to be investigated further in future experiments. Alternatively, the use of low-intensity US reduces the heating of underlying tissues and also minimizes the extent of cavitation phenomena [29]. Wang et al. 1993 [29] reported that application of mechanical stressors to the cytoskeleton could be reflected on cell metabolism with changes in gene expression. They also reported that modulating focal adhesion formation or changing extracellular matrix receptors number or location may alter cells sensitivity to a mechanical stimulus. In addition, Wang et al. 2004 also reported that nitric oxide was a major factor in mediating extracellular matrix released by LIPUS and induced osteoblasts to produce angiogenic factors after LIPUS application. Intermittent high-frequency acoustic pressure waves are a non-invasive form of mechanical stress using LIPUS protocol at frequencies ranging from 1.5-2 MHz and intensity of 30 mW/cm² [37].
Warden et al. 2001 [39] proposed that LIPUS increased the expression of c-fos and cyclooxygenase-2 genes and elevated mRNA levels for the bone matrix proteins alkaline phosphatase (ALP) and osteocalcin (OCN). In addition, Xing et al. 2012 [40] reported that LIPUS increased cell permeability by induced monoclonal antibody production through structural changes in cellular outer membrane. The acoustic pressure of low frequency ultrasound waves does not increase the tissue temperature more than 1°C and does not significantly alter cellular activity [41].

Conversely, other studies demonstrated that continuous mechanical stress may decrease the cellular activities as reflected on DNA content, ALP and calcium content [42]. The persistent mechanical stress may have reduced the activation of mechanosensitive cation channels in osteoblast-like cells [45]. Parvizi et al., 1999 [43] did not detect any effect of LIPUS on the expression of transforming growth factor-β, osteocalcin, alkaline phosphatase, and α (I)-procollagen genes in cultured osteoblasts. They noted that cell proliferation was not stimulated by ultrasound at 4, 6, 8 days at different intensities of 20 and 50 mW/cm². Their setting was however different from ours, or that of the clinically used LIPUS (30mW/cm²). Kinoshita et al. 2007 [44] reported that creating standing wave by direct contact of LIPUS transducer to the cultured cell in plate is one of the key elements in achieving successful sonoporation (ultrasound-induced cell membrane permeability) to establish a desired acoustic field.

Some of our study findings, notably the increased ALP at day 14 in the LIPUS group may be due to changes in cell membrane permeability by LIPUS. It has been reported that LIPUS cavitation results in changes in the permeability of cell membrane and calcium channels [43]. Those data suggest that the potential stimulatory effect of clinically applicable LIPUS treatment on these cells may occur at and beyond 14 days. Other recent studies on the effect of LIPUS on gingival and periodontal ligament cells showed similar results to ours that LIPUS at 30 mW/cm² for 5,10 and 20 minutes per day did not change ALP over 14 days [24, 45].

The lack of significant change in cell surface marker expression (as evaluated by the flowcytometry data in our experiment) may support, in part, our hypothesis that LIPUS maintains HUCPVC cell phenotypic characteristics after one day of treatment.

The significant increase of OPN mRNA by LIPUS compared to the sham group at day 14 as evaluated by Q-PCR is in agreement of previous study of the effect of LIPUS on gingival fibroblasts [24] regardless the difference in LIPUS daily treatment time between our study and previous study [24]. This could be due to the difference in cell behavior and multipotency of HUCPVCs compared to gingival fibroblasts.

The significant increase in PCNA mRNA (P<.01) by LIPUS compared to the sham control HUCPVCs without significant increase in cell number within the same period could be due to the fact that the increase in PCNA mRNA expression would take some time to have protein expression and consequent increase in cell proliferation. This rise in PCNA without a measurable increase in cell count in the LIPUS-treated, could also due to the short duration of LIPUS treatment in our study. This is supported by the findings of Yoon et al., 2009 [21] and may further validate some aspect of our hypothesis that LIPUS may increase PCNA (the proliferation gene of HUCPVCs) whilst maintaining their cell phenotypic characteristics after 14 days of treatment [21]. Experiments designed with a longer duration of LIPUS application may help further understanding of the biological behavior of HUCPVCs.

Although it has been hypothesized that LIPUS may increase blood flow around the fracture site during the application, this effect would extend for a period of time after removal of stimulus [46]. This may lead to maximizing the delivery of nutrients, metabolites, and growth factors. Also, Sena et al. 2005 [47] reported that LIPUS application resulted in elevated the expression of early response genes (c-jun, c-myc, Egr-1, cox-2) as well as bone differentiation marker genes osteonectin and osteopontin. The induction of those extracellular matrix genes represents the effect of LIPUS treatment.

The increased ALP, OPN, and OCN by LIPUS at day 14 were suggestive that LIPUS had an anabolic effect on HUCPVCs and may be helpful in the osteogenic differentiation of these cells. That finding was in agreement with previous reports that
LIPUS enhanced ALP, OPN, OCN in different cell types\textsuperscript{[24, 45]}. The increased NST expression indicated that LIPUS stimulation maintained the cellular characteristics of HUCPV cells. That is in disagreement with another study which showed that LIPUS increased NST in gingival fibroblasts\textsuperscript{[48]}. This again suggests that HUCPVCs are different from gingival fibroblasts regarding their multipotency. Several other studies support that the application of LIPUS on different type of cells may result in non-significant differences in cell proliferation\textsuperscript{[45-50]} and differentiation\textsuperscript{[24, 37, 49, 54]}. Our findings were consistent with the literature that studied mesenchymal stem cells\textsuperscript{[45, 49, 50, 52]} and chondrocytes\textsuperscript{[43, 48, 49, 50, 53]}, which postulated that the tissue mechanical stress induced by LIPUS may direct the cell efforts towards maintenance rather than proliferation and differentiation.

**Limitations of the study**

Application of LIPUS below tissue culture dish or plate may affect the actual LIPUS parameters that reaches treated cells in the tissue culture compared to applying LIPUS directly to the cells through culture medium\textsuperscript{[24, 51, 54]}. However, according to the report by Leskinen\textsuperscript{et al.}, 2012\textsuperscript{[25]}, similar LIPUS frequency decreased about 7% when passes through culture plate. This in our opinion is negligible, however warrants further investigation.

**5 Conclusion**

The optimum application of LIPUS for HUCPVC expansion is yet to be determined. Our study concluded that LIPUS application for 10 minutes per day for 14 days induced the expression of OSP and PCNA without significant increase in cell proliferation of HUCPVCs. Further investigation is required to test the effect of prolonged LIPUS applications for more than 14 days on several variables, including the potential for HUCPVCs proliferation.

**Acknowledgment**

The authors thank the University of Alberta (McIntyre Fund for Dentistry, the University of Alberta) and Saudi Arabian Cultural Bureau for financial support and funding of this project.

**References**


Published by Sciedu Press


